vs

Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $295.9M, roughly 1.1× Eastern Bankshares, Inc.). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs -18.2%, a 40.3% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 210.8%).

Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

EBC vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.1× larger
MDGL
$321.1M
$295.9M
EBC
Growing faster (revenue YoY)
EBC
EBC
+499.8% gap
EBC
710.6%
210.8%
MDGL
Higher net margin
EBC
EBC
40.3% more per $
EBC
22.1%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EBC
EBC
MDGL
MDGL
Revenue
$295.9M
$321.1M
Net Profit
$65.3M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
22.1%
-18.2%
Revenue YoY
710.6%
210.8%
Net Profit YoY
-34.4%
1.4%
EPS (diluted)
$0.29
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EBC
EBC
MDGL
MDGL
Q1 26
$295.9M
Q4 25
$37.5M
$321.1M
Q3 25
$241.5M
$287.3M
Q2 25
$244.9M
$212.8M
Q1 25
$31.1M
$137.3M
Q4 24
$216.5M
$103.3M
Q3 24
$203.4M
$62.2M
Q2 24
$154.0M
Net Profit
EBC
EBC
MDGL
MDGL
Q1 26
$65.3M
Q4 25
$99.5M
$-58.6M
Q3 25
$106.1M
$-114.2M
Q2 25
$100.2M
$-42.3M
Q1 25
$-217.7M
$-73.2M
Q4 24
$60.8M
$-59.4M
Q3 24
$-6.2M
$-107.0M
Q2 24
$26.3M
Gross Margin
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
-18.6%
Q3 25
38.9%
-39.7%
Q2 25
41.0%
-22.2%
Q1 25
-590.9%
-57.8%
Q4 24
33.3%
-64.8%
Q3 24
-1.6%
-187.1%
Q2 24
24.7%
Net Margin
EBC
EBC
MDGL
MDGL
Q1 26
22.1%
Q4 25
265.6%
-18.2%
Q3 25
44.0%
-39.8%
Q2 25
40.9%
-19.9%
Q1 25
-699.2%
-53.4%
Q4 24
28.1%
-57.5%
Q3 24
-3.0%
-172.0%
Q2 24
17.1%
EPS (diluted)
EBC
EBC
MDGL
MDGL
Q1 26
$0.29
Q4 25
$0.48
$-2.55
Q3 25
$0.53
$-5.08
Q2 25
$0.50
$-1.90
Q1 25
$-1.08
$-3.32
Q4 24
$0.29
$-2.50
Q3 24
$-0.03
$-4.92
Q2 24
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EBC
EBC
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$551.7M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$4.3B
$602.7M
Total Assets
$30.6B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EBC
EBC
MDGL
MDGL
Q1 26
$551.7M
Q4 25
$507.6M
$198.7M
Q3 25
$703.4M
$295.7M
Q2 25
$948.3M
$186.2M
Q1 25
$609.0M
$183.6M
Q4 24
$1.9B
$100.0M
Q3 24
$1.7B
$232.7M
Q2 24
$1.4B
Total Debt
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
EBC
EBC
MDGL
MDGL
Q1 26
$4.3B
Q4 25
$4.3B
$602.7M
Q3 25
$3.8B
$625.7M
Q2 25
$3.7B
$696.0M
Q1 25
$3.6B
$710.6M
Q4 24
$3.6B
$754.4M
Q3 24
$3.7B
$777.2M
Q2 24
$3.0B
Total Assets
EBC
EBC
MDGL
MDGL
Q1 26
$30.6B
Q4 25
$30.6B
$1.3B
Q3 25
$25.5B
$1.4B
Q2 25
$25.5B
$1.0B
Q1 25
$25.0B
$996.6M
Q4 24
$25.6B
$1.0B
Q3 24
$25.5B
$1.1B
Q2 24
$21.0B
Debt / Equity
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EBC
EBC
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
$432.4M
$-133.5M
Q3 25
$157.1M
$79.8M
Q2 25
$123.9M
$-47.1M
Q1 25
$47.3M
$-88.9M
Q4 24
$283.8M
$-104.5M
Q3 24
$108.3M
$-67.0M
Q2 24
$54.3M
Free Cash Flow
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
FCF Margin
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Capex Intensity
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Cash Conversion
EBC
EBC
MDGL
MDGL
Q1 26
Q4 25
4.35×
Q3 25
1.48×
Q2 25
1.24×
Q1 25
Q4 24
4.67×
Q3 24
Q2 24
2.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EBC
EBC

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons